Peter is an experienced commercial leader in molecular diagnostics and genomics focused on nascent market development of disruptive innovations. Prior to joining Pacific Edge, he was based in Boston, USA for a number of molecular diagnostic leadership roles. Most recently the Chief Commercial Officer at Eurofins Transplant Genomics (TGI), a transplant diagnostics company focused on revolutionizing post-transplant care for kidney transplant recipients with non-invasive biomarkers he was responsible for scaling the commercial team behind TruGraf (now OmniGraf), the only CMS-reimbursed test for subclinical organ rejection. Prior to TGI, Peter was CEO at Omixon Inc, a molecular diagnostics company focused on the pre-transplant market, world leader in HLA typing by NGS, and recipient of the Innovation Grand Prize among all companies in Hungary in 2018. Omixon was acquired by Werfen in 2024. Prior to his US career, Peter worked at Auckland-based Biomatters, the creators of Geneious – software specializing in translating genetic and genomic data into biological insights for researchers and medical insights for clinicians. Biomatters was acquired by GraphPad in 2019.

Grant is an experienced financial executive and chartered accountant, who brings significant financial experience to the role. Prior to joining Pacific Edge in late 2019, Grant was Chief Financial and Operating Officer for Dunedin-based company, TracMap, where he was responsible for leading the financial management and operations across the company. Prior to that, Grant worked in executive finance roles at Westpac, including as Head of Finance for Westpac New Zealand. During his time with Westpac, he headed the finance team for New Zealand’s largest financial transaction, the local incorporation of Westpac New Zealand.

Tamer joined Pacific Edge in June 2022 and brings to the company a depth of experience in clinical, medical research, and commercial roles in urological medicine in Egypt and the USA. Prior to joining the company, he was Senior Director of Oncology Clinical Development at Exact Sciences and prior to that he was Global Therapy Area Head, Urology, Medical Affairs at the global pharmaceutical company Allergan. He is a graduate of the Ain Shams University Medical School in Cairo. He also holds Masters and Doctoral degrees in urology and molecular medicine and has held residency, postdoctoral and research roles in Egypt and the US

Darrell is a Chartered Biologist with over 40 years experience in senior roles in pharmaceutical research and development, immunodiagnostics, and device development for drug delivery across human and animal health, technical operations and customer-facing roles in the UK, Europe and New Zealand. Prior to joining Pacific Edge, Darrell held several roles at Argenta, an Auckland based animal pharmaceutical manufacturer, including VP of Business Development, Head of Global Pharmaceutical Sciences and Director of Product Development. His last role in Europe was leading UCB’s large molecule sterile drug delivery and patient solution technologies teams, developing drug/device combination products which were approved by both FDA and EMEA.

Justin joined Pacific Edge in 2004, bringing a robust background in medical laboratory testing, diagnostics, and cancer genetics. He has played a pivotal role in the development and commercialization of the Cxbladder suite of products from their inception. Currently, Justin leads Pacific Edge’s scientific Research and Development program, focusing on developing novel products aimed at improving patient outcomes through early detection and management of cancer. Justin is dedicated to advancing medical science and improving patient care through innovative diagnostic solutions. His leadership and expertise continue to drive Pacific Edge’s mission to provide leading solutions for the early detection and management of cancer.

Parry has led the science, research and development at Pacific Edge from its early days. As one of the founding scientists and a member of the Scientific Advisory Board of the Company, Parry is the architect of many of the Company’s product prototypes. Parry’s focus is to bring his world class skills and experience on the step change in biotechnology for the Company’s next generation of products.

Glen joined Pacific Edge in April 2023 having spent more than 20 years in Asia Pacific markets with life science/ diagnostic companies such as BD (Becton Dickinson) and Bio-Rad Laboratories. Glen has had extensive hands-on commercial and goto-market experience in China, Korea, Taiwan, SE Asian countries, Australia and New Zealand both directly and via distribution partners. His sales and marketing experience spans, life science research, diagnostic instrumentation, as well as launching a new Oncology test for Cervical Cancer Screening generating over US$38M pa in revenues within APAC. Glen has sold at the executive level for many years and developed Key Opinion Leader networks to support innovative technology introduction in the medical diagnostics sector, including his former role as Global Private Pathology Director at BD Diagnostics. Glen’s qualifications include: Bachelor of Science (Genomics), Masters of Management (Marketing Management & Finance) from Macquarie Graduate School of Management.

Zoe joined Pacific Edge in January 2025 as Global Head of People & Culture. Prior to joining Pacific Edge Zoe worked in a number of roles and industries in the UK and New Zealand most recently with Fisher & Paykel Appliances as Global Total Rewards Consultant. Zoe’s roles and experiences gives her a unique breadth and depth to her HR and Leadership expertise.

As Global Head of People & Culture Zoe’s passionate about people and performance and leads the people strategy and initiatives that streamline and enhance all touchpoints of the employee lifecycle and experience. Zoe champions an equitable and inclusive culture and believes in building organisational capability and accountability to drive a high-performance culture aligned to strategy while delivering value to our customers.